<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7403098\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="long as the COVID-19 resource centre remains active. Abstract Coronavirus" exact="Disease" post="2019 (COVID-19) caused by a Severe Acute Respiratory Syndrome"/>
  <result pre="remains active. Abstract Coronavirus Disease 2019 (COVID-19) caused by a" exact="Severe" post="Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in"/>
  <result pre="active. Abstract Coronavirus Disease 2019 (COVID-19) caused by a Severe" exact="Acute" post="Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan,"/>
  <result pre="Abstract Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute" exact="Respiratory" post="Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China"/>
  <result pre="Coronavirus Disease 2019 (COVID-19) caused by a Severe Acute Respiratory" exact="Syndrome" post="Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan, China at"/>
  <result pre="a highly pathogenic zoonotic virus and closely related to the" exact="Severe" post="Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome"/>
  <result pre="highly pathogenic zoonotic virus and closely related to the Severe" exact="Acute" post="Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus"/>
  <result pre="pathogenic zoonotic virus and closely related to the Severe Acute" exact="Respiratory" post="Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV)."/>
  <result pre="to the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV). The COVID-19 was declared as a"/>
  <result pre="the Severe Acute Respiratory Coronavirus (SARS-CoV) and Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV). The COVID-19 was declared as a global"/>
  <result pre="are considered as reliable biomarkers in severe COVID-19 disease. â€¢The" exact="viral" post="spike glycoprotein encoded by spike gene facilitates viral binding"/>
  <result pre="disease. â€¢The viral spike glycoprotein encoded by spike gene facilitates" exact="viral" post="binding to ACE2 receptor of the host cell membrane."/>
  <result pre="pathogenic and transmissible disease, caused by a beta coronavirus called" exact="Severe" post="Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (Khan et al., 2020b)."/>
  <result pre="and transmissible disease, caused by a beta coronavirus called Severe" exact="Acute" post="Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) (Khan et al., 2020b). COVID-19"/>
  <result pre="transmissible disease, caused by a beta coronavirus called Severe Acute" exact="Respiratory" post="Syndrome Coronavirus-2 (SARS-CoV-2) (Khan et al., 2020b). COVID-19 originated"/>
  <result pre="disease, caused by a beta coronavirus called Severe Acute Respiratory" exact="Syndrome" post="Coronavirus-2 (SARS-CoV-2) (Khan et al., 2020b). COVID-19 originated in"/>
  <result pre="considered the continuation of previous outbreaks of coronaviruses (CoV), namely" exact="Severe" post="Acute Respiratory Syndrome (SARS-) and Middle East Respiratory Syndrome"/>
  <result pre="the continuation of previous outbreaks of coronaviruses (CoV), namely Severe" exact="Acute" post="Respiratory Syndrome (SARS-) and Middle East Respiratory Syndrome (MERS)"/>
  <result pre="continuation of previous outbreaks of coronaviruses (CoV), namely Severe Acute" exact="Respiratory" post="Syndrome (SARS-) and Middle East Respiratory Syndrome (MERS) that"/>
  <result pre="of previous outbreaks of coronaviruses (CoV), namely Severe Acute Respiratory" exact="Syndrome" post="(SARS-) and Middle East Respiratory Syndrome (MERS) that emerged"/>
  <result pre="(CoV), namely Severe Acute Respiratory Syndrome (SARS-) and Middle East" exact="Respiratory" post="Syndrome (MERS) that emerged in 2003 and 2012, respectively"/>
  <result pre="namely Severe Acute Respiratory Syndrome (SARS-) and Middle East Respiratory" exact="Syndrome" post="(MERS) that emerged in 2003 and 2012, respectively (Khan"/>
  <result pre="2020). Moreover, an earlier claim that pangolin could be an" exact="intermediate" post="source of transmission from bat to humans was later"/>
  <result pre="SARS-CoV-2 is highly transmissible and can infect both lungs with" exact="atypical" post="clinical symptoms, resulting in either misdiagnosis or missed diagnosis"/>
  <result pre="transmitted from human to human through inhalation or contact with" exact="respiratory" post="droplets of infected individuals. The time from infection to"/>
  <result pre="contact with respiratory droplets of infected individuals. The time from" exact="infection" post="to the manifestation of symptoms ranges from 2 to"/>
  <result pre="a wide spectrum of diseases ranging from mild to severe" exact="respiratory" post="syndrome influenza-like illness with lower respiratory tract symptoms, loss"/>
  <result pre="wide spectrum of diseases ranging from mild to severe respiratory" exact="syndrome" post="influenza-like illness with lower respiratory tract symptoms, loss of"/>
  <result pre="ranging from mild to severe respiratory syndrome influenza-like illness with" exact="lower" post="respiratory tract symptoms, loss of taste and smell, and"/>
  <result pre="from mild to severe respiratory syndrome influenza-like illness with lower" exact="respiratory" post="tract symptoms, loss of taste and smell, and severe"/>
  <result pre="mild in most cases, however, it can be a life-threatening" exact="disease" post="by developing severe pneumonia, acute respiratory distress syndrome (ARDS),"/>
  <result pre="it can be a life-threatening disease by developing severe pneumonia," exact="acute" post="respiratory distress syndrome (ARDS), high fever, headache, and multi-organ"/>
  <result pre="can be a life-threatening disease by developing severe pneumonia, acute" exact="respiratory" post="distress syndrome (ARDS), high fever, headache, and multi-organ dysfunction"/>
  <result pre="a life-threatening disease by developing severe pneumonia, acute respiratory distress" exact="syndrome" post="(ARDS), high fever, headache, and multi-organ dysfunction (Singhal, 2020)."/>
  <result pre="virus entry mediating cellular receptors. We further discussed therapeutic options," exact="susceptibility to" post="the disease, and immunological responses that could play a"/>
  <result pre="elevated ACE and Ang II are bad prognosis for severe" exact="pneumonia" post="(Sun et al., 2020). Whether SARS-CoV-2 can attack neurological"/>
  <result pre="the manifestations including headache and nausea in response to COVID-19" exact="infection" post="suggest the effect of SARS-CoV-2 on the neurological system."/>
  <result pre="the effect of SARS-CoV-2 on the neurological system. Fig. 1" exact="Viral" post="entry. COVID-19 particles attach to ACE2 receptor on the"/>
  <result pre="Simultaneously, ssRNA is replicated via RNA-dependent RNA polymerase to produce" exact="viral" post="RNA. Next step is to produce empty capsids and"/>
  <result pre="capsids and them to pack these capsids with RNA. The" exact="viral" post="particles are ready depart via exocytosis. 3 Origin of"/>
  <result pre="to bats, however, the transmission to humans through an unknown" exact="intermediate" post="animal in Wuhan, China is still controversial (Khan et"/>
  <result pre="which constitute 31% of their virome. They are immune to" exact="viral infection" post="and the characteristics such as higher species diversity (over"/>
  <result pre="constitute 31% of their virome. They are immune to viral" exact="infection" post="and the characteristics such as higher species diversity (over"/>
  <result pre="longer life span (over 30 years), and migration transmit the" exact="viral" post="pathogens across the political and geographical boundaries (Allocati et"/>
  <result pre="species were similar to that previously isolated from porcine epidemic" exact="diarrhea" post="virus (PEDV), indicating a common ancestor of the CoVs"/>
  <result pre="genomes of SARS-CoV-2 and classified them into two major genotypes;" exact="type I" post="and Type II. Type I is further sub-divided into"/>
  <result pre="and classified them into two major genotypes; type I and" exact="Type II." post="Type I is further sub-divided into type IA and"/>
  <result pre="them into two major genotypes; type I and Type II." exact="Type I" post="is further sub-divided into type IA and IB. Furthermore,"/>
  <result pre="that type IA is similar to the ancestral SARS-CoV-2, whereas" exact="type II" post="was probably evolved from the type I and prevalent"/>
  <result pre="ancestral SARS-CoV-2, whereas type II was probably evolved from the" exact="type I" post="and prevalent in the infections. We generated a bioinformatic"/>
  <result pre="these viruses into humans was likely facilitated by independent unknown" exact="external" post="factors. Our findings indicated that SARS-CoV-2 is most probably"/>
  <result pre="purged from the most similar sequences and midpoint rooted. 3.1" exact="Immunological" post="responses In COVID-19, the immune response is less rigorous,"/>
  <result pre="people and individuals with underlying conditions are prone to develop" exact="Acute" post="Respiratory Distress Syndrome (ARDS) and death (Khan et al.,"/>
  <result pre="and individuals with underlying conditions are prone to develop Acute" exact="Respiratory" post="Distress Syndrome (ARDS) and death (Khan et al., 2020a)."/>
  <result pre="with underlying conditions are prone to develop Acute Respiratory Distress" exact="Syndrome" post="(ARDS) and death (Khan et al., 2020a). However, fever"/>
  <result pre="showed an increased level in severe cases, suggesting that the" exact="primary" post="target of COVID-19 infection is T lymphocytes (Qin et"/>
  <result pre="in severe cases, suggesting that the primary target of COVID-19" exact="infection" post="is T lymphocytes (Qin et al., 2020). Similarly, Shi"/>
  <result pre="which can be considered as reliable biomarkers in severe COVID-19" exact="disease" post="(Fig. 3 ). Furthermore, analysis of ILs in the"/>
  <result pre="mild ones. However, no statistical differences in the expression of" exact="tumor" post="necrosis factor-alpha (TNF-Î±), Interleukins (IL-1, IL-8, IL-10), High-sensitivity C-reactive"/>
  <result pre="tumor necrosis factor-alpha (TNF-Î±), Interleukins (IL-1, IL-8, IL-10), High-sensitivity C-reactive" exact="Protein" post="(hs-CRP), lymphocyte count, and lactate dehydrogenase (LDH) between the"/>
  <result pre="risk, whereas those with blood group O are comparatively at" exact="lower" post="risk for contracting COVID-19 infection (Zhao et al., 2020)."/>
  <result pre="group O are comparatively at lower risk for contracting COVID-19" exact="infection" post="(Zhao et al., 2020). Although it is very early"/>
  <result pre="previous study on SARS, where SARS-CoV was reported with a" exact="lower" post="rate of infectiousness in individuals with blood group O"/>
  <result pre="trigger B cells to transform into memory cells carrying the" exact="viral" post="antigen. Then plasma cells produce the viral antibody to"/>
  <result pre="cells carrying the viral antigen. Then plasma cells produce the" exact="viral" post="antibody to defend the cells against the next viral"/>
  <result pre="the viral antibody to defend the cells against the next" exact="viral" post="attack. APC: antigen presenting cells, TCR: T-cell receptors, IL:"/>
  <result pre="Ag: antigen, TGF-Î±: transforming growth factor alpha. 3.2 Clinical manifestations" exact="Pneumonia" post="appears to be the most frequent manifestation of SARS-CoV-2"/>
  <result pre="of SARS-CoV-2 infection, characterized primarily by fever, cough, dyspnea, and" exact="bilateral" post="infiltrates on chest imaging (Khan et al., 2020a). Li"/>
  <result pre="characterized primarily by fever, cough, dyspnea, and bilateral infiltrates on" exact="chest" post="imaging (Khan et al., 2020a). Li et al. (2020c),"/>
  <result pre="also reported less common symptoms including headache or dizziness (12.1%)," exact="diarrhea" post="(4.8%), and nausea or vomiting (3.9%). Furthermore, laboratory tests"/>
  <result pre="(64.5%) and an elevation in CRP (44.3%), LDH (28.3%), and" exact="leukocytopenia" post="(29.4%). In the same study, Li et al. (2020d),"/>
  <result pre="Li et al. (2020d), found that lymphocytopenia, eosinophil cytopenia, and" exact="leukopenia" post="were observed in 10 COVID-19 patients. In another study"/>
  <result pre="study. Overall, these indications suggest that LDH and High-sensitivity C-reactive" exact="Protein" post="(Î±-HBDH) could be reliable biomarkers for investigating COVID-19. Moreover,"/>
  <result pre="140 COVID-19 patients, Zhang et al. (2020b), reported eosinopenia and" exact="lymphopenia" post="as potential diagnostic factors for the disease while asthma"/>
  <result pre="reported eosinopenia and lymphopenia as potential diagnostic factors for the" exact="disease" post="while asthma and chronic obstructive pulmonary disease (COPD) are"/>
  <result pre="and lymphopenia as potential diagnostic factors for the disease while" exact="asthma" post="and chronic obstructive pulmonary disease (COPD) are unlikely to"/>
  <result pre="as potential diagnostic factors for the disease while asthma and" exact="chronic" post="obstructive pulmonary disease (COPD) are unlikely to be the"/>
  <result pre="diagnostic factors for the disease while asthma and chronic obstructive" exact="pulmonary" post="disease (COPD) are unlikely to be the risk factors."/>
  <result pre="factors for the disease while asthma and chronic obstructive pulmonary" exact="disease" post="(COPD) are unlikely to be the risk factors. Older"/>
  <result pre="for the disease while asthma and chronic obstructive pulmonary disease" exact="(COPD)" post="are unlikely to be the risk factors. Older age"/>
  <result pre="the risk factors. Older age and underlying health conditions including" exact="cardiovascular" post="problems, hypertension, diabetes, and pulmonary aberrations were found to"/>
  <result pre="and underlying health conditions including cardiovascular problems, hypertension, diabetes, and" exact="pulmonary" post="aberrations were found to be associated with the development"/>
  <result pre="patients. 4 Therapeutic options The overall risks associated with COVID-19" exact="infection" post="can be mitigated with effective eradication of the infection."/>
  <result pre="combination with chloroquine or interferon beta showed effectiveness against COVID-19" exact="infection" post="(Sheahan et al., 2020). In addition, W.H.O and C.D.C"/>
  <result pre="recommend glucocorticoids should not be used in patients with COVID-19" exact="pneumonia" post="unless required such in case of exacerbation of the"/>
  <result pre="pneumonia unless required such in case of exacerbation of the" exact="chronic" post="obstructive pulmonary disease. Nevertheless, the development of clinical drugs"/>
  <result pre="required such in case of exacerbation of the chronic obstructive" exact="pulmonary" post="disease. Nevertheless, the development of clinical drugs for coronaviruses"/>
  <result pre="screening of a large number of molecules in a very" exact="short" post="time. They identified 1000 potential ligands for the main"/>
  <result pre="Chinese medicines, which have been found effective against the COVID-19" exact="infection" post="(Chan et al., 2020). Previous studies have shown that"/>
  <result pre="toxic effects of chloroquine such as increasing the risk for" exact="cardiovascular" post="disorders have limited its use against the COVID-19 (Frisk-Holmberg"/>
  <result pre="chloroquine such as increasing the risk for cardiovascular disorders have" exact="limited" post="its use against the COVID-19 (Frisk-Holmberg et al., 1983)."/>
  <result pre="cells, where the suppression was mainly related to the targeting" exact="viral" post="nonstructural protein 15 (nsp 15) (Matsuyama et al., 2020)."/>
  <result pre="al., 2020). It is expected that inhaled ciclesonide can reduce" exact="viral" post="replication and host inflammation in the lungs. ACE2 negatively"/>
  <result pre="a carboxypeptidase. SARS-CoV-2 was found to attack cells using this" exact="type I" post="integral membrane protein (Matsuyama et al., 2020). Depletion of"/>
  <result pre="of the RAS, which then leads to the progression of" exact="acute" post="severe pneumonia. Thus, inhibiting ACE2 may alleviate pneumonia in"/>
  <result pre="progression of acute severe pneumonia. Thus, inhibiting ACE2 may alleviate" exact="pneumonia" post="in COVID-19 patients, provided that blood pressure is controlled"/>
  <result pre="membrane and this ACE2 could be a target to prevent" exact="viral" post="entry. Moreover, Transmembrane Serine Protease 2 (TMPRSS2) is helper"/>
  <result pre="Serine Protease 2 (TMPRSS2) is helper membrane protein for the" exact="viral" post="entry, on which any modification could control cellular infection."/>
  <result pre="could be applied to ACE2 receptor, which when blocked, the" exact="viral" post="particle would not be able to enter the host"/>
  <result pre="against spike protein is also a proposed intervention strategy. 5" exact="Susceptibility to" post="COVID-19 In terms of clinical manifestations, lung cancer and"/>
  <result pre="strategy. 5 Susceptibility to COVID-19 In terms of clinical manifestations," exact="lung cancer" post="and COVID-19 are similar, making it difficult for clinicians"/>
  <result pre="5 Susceptibility to COVID-19 In terms of clinical manifestations, lung" exact="cancer" post="and COVID-19 are similar, making it difficult for clinicians"/>
  <result pre="it difficult for clinicians to differentiate (Yang et al., 2020a)." exact="Lung cancer" post="patients receiving systemic immunosuppressive agents are more prone to"/>
  <result pre="difficult for clinicians to differentiate (Yang et al., 2020a). Lung" exact="cancer" post="patients receiving systemic immunosuppressive agents are more prone to"/>
  <result pre="to differentiate (Yang et al., 2020a). Lung cancer patients receiving" exact="systemic" post="immunosuppressive agents are more prone to be infected with"/>
  <result pre="while five of these 18 cases had a history of" exact="lung cancer" post="(Xia et al., 2020). However, any conclusion to associate"/>
  <result pre="five of these 18 cases had a history of lung" exact="cancer" post="(Xia et al., 2020). However, any conclusion to associate"/>
  <result pre="(Xia et al., 2020). However, any conclusion to associate COVID-19" exact="infection" post="with cancer should be drawn carefully, as no convincing"/>
  <result pre="al., 2020). However, any conclusion to associate COVID-19 infection with" exact="cancer" post="should be drawn carefully, as no convincing evidence is"/>
  <result pre="no convincing evidence is available to confirm that patients with" exact="cancer" post="have an increased risk of being infected with COVID-19."/>
  <result pre="receptor protein. An animal model expressing DPP-IV receptor on the" exact="pulmonary" post="alveolar cells has been designed to elucidate how diabetes"/>
  <result pre="the pulmonary alveolar cells has been designed to elucidate how" exact="diabetes" post="worsens disease severity, and the obtained data indicated an"/>
  <result pre="alveolar cells has been designed to elucidate how diabetes worsens" exact="disease" post="severity, and the obtained data indicated an association of"/>
  <result pre="disease severity, and the obtained data indicated an association of" exact="diabetes" post="with macrophage infiltrates (Bloomgarden, 2020). Therefore, diabetic patients seem"/>
  <result pre="Therefore, diabetic patients seem to be more susceptible to COVID-19" exact="infection" post="than others. Yang et al., (!!! INVALID CITATION (Yang"/>
  <result pre="that out of 52 COVID-19 patients, 32 were suffering from" exact="chronic" post="diseases such as cerebrovascular diseases (22%) and diabetes (22%)."/>
  <result pre="suffering from chronic diseases such as cerebrovascular diseases (22%) and" exact="diabetes" post="(22%). Meanwhile, Guan et al. (2020), analyzed data from"/>
  <result pre="from 1099 COVID-19 patients and found that 173 patients had" exact="chronic" post="diseases: diabetes mellitus (16.2%), coronary heart diseases (5.8%), cerebrovascular"/>
  <result pre="COVID-19 patients and found that 173 patients had chronic diseases:" exact="diabetes mellitus" post="(16.2%), coronary heart diseases (5.8%), cerebrovascular disease (2.3%), and"/>
  <result pre="that 173 patients had chronic diseases: diabetes mellitus (16.2%), coronary" exact="heart" post="diseases (5.8%), cerebrovascular disease (2.3%), and hypertension (23.7%). The"/>
  <result pre="had chronic diseases: diabetes mellitus (16.2%), coronary heart diseases (5.8%)," exact="cerebrovascular disease" post="(2.3%), and hypertension (23.7%). The expression of ACE2 is"/>
  <result pre="chronic diseases: diabetes mellitus (16.2%), coronary heart diseases (5.8%), cerebrovascular" exact="disease" post="(2.3%), and hypertension (23.7%). The expression of ACE2 is"/>
  <result pre="mellitus (16.2%), coronary heart diseases (5.8%), cerebrovascular disease (2.3%), and" exact="hypertension" post="(23.7%). The expression of ACE2 is elevated in diabetic"/>
  <result pre="increase the expression of ACE2. Consequently, this would facilitate the" exact="infection" post="with SARS-CoV-2, which uses this protein as an entry"/>
  <result pre="In addition, ACE2 is not only expressed in the alveolar" exact="epithelial" post="cells, but also in the heart, gastrointestinal tract, kidney,"/>
  <result pre="and thus makes these tissues and organs susceptible to COVID-19" exact="infection" post="and damage to multiple organs (Liu et al., 2020;"/>
  <result pre="conducted by Li et al. (2020a), summarized the proportion of" exact="cardiovascular disease" post="(16.4%), diabetes (9.7%), and hypertension (17.1%) in COVID-19 patients."/>
  <result pre="by Li et al. (2020a), summarized the proportion of cardiovascular" exact="disease" post="(16.4%), diabetes (9.7%), and hypertension (17.1%) in COVID-19 patients."/>
  <result pre="et al. (2020a), summarized the proportion of cardiovascular disease (16.4%)," exact="diabetes" post="(9.7%), and hypertension (17.1%) in COVID-19 patients. They concluded"/>
  <result pre="summarized the proportion of cardiovascular disease (16.4%), diabetes (9.7%), and" exact="hypertension" post="(17.1%) in COVID-19 patients. They concluded that patients with"/>
  <result pre="(17.1%) in COVID-19 patients. They concluded that patients with previous" exact="cardiovascular" post="diseases may have an increased risk of developing severe"/>
  <result pre="have an increased risk of developing severe conditions, while, COVID-19" exact="infection" post="can exacerbate the damage of the heart. In COVID-19"/>
  <result pre="the damage of the heart. In COVID-19 patients with underlying" exact="cardiovascular disease," post="hypersensitive C-reactive protein, and serum creatinine levels were elevated"/>
  <result pre="levels were elevated compared with COVID-19 patients with no underlying" exact="cardiovascular disease." post="Overall these indications suggest that COVID-19 can affect cardiovascular"/>
  <result pre="cardiovascular disease. Overall these indications suggest that COVID-19 can affect" exact="cardiovascular" post="function and lead to myocardial injury (Chen et al.,"/>
  <result pre="nt), and ORF8 (366Â nt) (Wu et al., 2020). The" exact="viral" post="spike (S) glycoprotein encoded by spike gene facilitates viral"/>
  <result pre="The viral spike (S) glycoprotein encoded by spike gene facilitates" exact="viral" post="binding to ACE2 receptor of the host cell membrane."/>
  <result pre="to ACE2 receptor of the host cell membrane. After the" exact="viral" post="fusion and entry through the ACE2 receptor, its RNA"/>
  <result pre="16Â nsps are produced. This cleavage property is mediated by" exact="viral" post="proteases nsp 3 and nsp 5 that contain a"/>
  <result pre="who meet specified criteria, in addition to testing for other" exact="respiratory" post="pathogens, the CDC recommends collection of specimens to test"/>
  <result pre="collection of specimens to test for COVID-19 virus from the" exact="upper" post="respiratory tract (nasopharyngeal and oropharyngeal swab) and, if possible,"/>
  <result pre="of specimens to test for COVID-19 virus from the upper" exact="respiratory" post="tract (nasopharyngeal and oropharyngeal swab) and, if possible, the"/>
  <result pre="respiratory tract (nasopharyngeal and oropharyngeal swab) and, if possible, the" exact="lower" post="respiratory tract (sputum, tracheal aspirate, or bronchoalveolar lavage). Additional"/>
  <result pre="tract (nasopharyngeal and oropharyngeal swab) and, if possible, the lower" exact="respiratory" post="tract (sputum, tracheal aspirate, or bronchoalveolar lavage). Additional specimens"/>
  <result pre="which is based on the detection of unique sequences of" exact="viral" post="RNA. In routine-based testing for COVID-19 patients, the presence"/>
  <result pre="the presence of SARS-COV-2 is determined through the detection of" exact="viral" post="genes namely N, E, S, and RdRP using real-time"/>
  <result pre="methods require expert personnel and expensive laboratory equipment whereas, low" exact="viral" post="load in the throat or nasal swab of patients"/>
  <result pre="(NTS) method can be used to detect SARS-CoV-2 and other" exact="respiratory" post="viruses simultaneously within 6â€&quot;10Â h. Nonetheless, an efficient, rapid,"/>
  <result pre="has been widely used as an immune-stimulant in patients with" exact="avian influenza" post="virus, West Nile virus, influenza virus, hepatitis C virus,"/>
  <result pre="patients with avian influenza virus, West Nile virus, influenza virus," exact="hepatitis C" post="virus, papillomavirus, herpes virus, and many other viruses. Although"/>
  <result pre="virus, West Nile virus, influenza virus, hepatitis C virus, papillomavirus," exact="herpes" post="virus, and many other viruses. Although the efficacy of"/>
  <result pre="immunosensors that can be utilized for the detection of pathogenic" exact="viral" post="organisms. Electrochemistry guided immunosensors have become feasible because of"/>
  <result pre="The immunosensors with various microchip electrodes were used to detect" exact="avian influenza" post="A (H7N9) virus (Han et al., 2016) and H1N1"/>
  <result pre="and H1N1 type influenza virus (Singh et al., 2017), human" exact="immunodeficiency" post="virus (HIV), human papillomavirus (HPV) (Huang et al., 2015),"/>
  <result pre="infection. The need for a faster sensing process at a" exact="lower" post="detection limit is an important but challenging strategy. Designing"/>
  <result pre="for multi detection purposes. 9 Conclusion The deadly and highly" exact="infectious" post="COVID-19 pandemic is spreading unstoppably in almost all countries"/>
  <result pre="P., Masulli, M., Di Ilio, C., De Laurenzi, V., Bat-man" exact="disease" post="transmission: zoonotic pathogens from wildlife reservoirs to human populations."/>
  <result pre="myocardial injury in patients with COVID-19 and association between concomitant" exact="cardiovascular" post="diseases and severity of COVID-19]Zhonghua Xinxueguanbing Zazhi482020E008 ChenL.LiuH.G.LiuW.LiuJ.LiuK.ShangJ.DengY.WeiS.[Analysis of"/>
  <result pre="pneumonia]Zhonghua Jiehe He Huxi Zazhi43202020320832164089 ChowdhuryA.D.TakemuraK.LiT.-C.SuzukiT.ParkE.Y.Electrical pulse-induced electrochemical biosensor for" exact="hepatitis E" post="virus detectionNat. Commun.102019373731427581 ColsonP.RolainJ.M.RaoultD.Chloroquine for the 2019 novel coronavirus"/>
  <result pre="4): implications for the origin and emergence of Middle East" exact="respiratory" post="syndrome coronavirusVirol. J.10201330410.1186/1743-422X-10-30424107353 Di PierroF.BertuccioliA.CavecchiaI.Possible therapeutic role of a"/>
  <result pre="implications for the origin and emergence of Middle East respiratory" exact="syndrome" post="coronavirusVirol. J.10201330410.1186/1743-422X-10-30424107353 Di PierroF.BertuccioliA.CavecchiaI.Possible therapeutic role of a highly"/>
  <result pre="infected with 2019 novel coronavirusMinerva Gastroenterol. Dietol.662202017217610.23736/S1121-421X.20.02697-532162896 FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet."/>
  <result pre="2019 novel coronavirusMinerva Gastroenterol. Dietol.662202017217610.23736/S1121-421X.20.02697-532162896 FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet. Resp. Med.842020e2110.1016/S2213-2600(20)30116-8 Frisk-HolmbergM.BergqvistY.EnglundU.Chloroquine"/>
  <result pre="Resp. Med.842020e2110.1016/S2213-2600(20)30116-8 Frisk-HolmbergM.BergqvistY.EnglundU.Chloroquine intoxication [letter]Br. J. Clin. Pharmacol.1519835025036849790 GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.PenzarD.PerlmanS.PoonL.L.M.SamborskiyD.SidorovI.A.SolaI.ZiebuhrJ.Severe" exact="Acute" post="Respiratory Syndrome-Related Coronavirus: the Species and its Viruses â€&quot;"/>
  <result pre="Med.842020e2110.1016/S2213-2600(20)30116-8 Frisk-HolmbergM.BergqvistY.EnglundU.Chloroquine intoxication [letter]Br. J. Clin. Pharmacol.1519835025036849790 GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.L.LauberC.LeontovichA.M.NeumanB.W.PenzarD.PerlmanS.PoonL.L.M.SamborskiyD.SidorovI.A.SolaI.ZiebuhrJ.Severe Acute" exact="Respiratory" post="Syndrome-Related Coronavirus: the Species and its Viruses â€&quot; a"/>
  <result pre="Statement of the Coronavirus Study GroupBioRxiv202010.1101/02.07.9378622020 GuanW.-j.NiZ.-y.HuY.LiangW.-h.OuC.-q.HeJ.-x.LiuL.ShanH.LeiC.-l.HuiD.S.C.DuB.LiL.-j.ZengG.YuenK.-Y.ChenR.-c.TangC.-l.WangT.ChenP.-y.XiangJ.LiS.-y.WangJ.-l.LiangZ.-j.PengY.-x.WeiL.LiuY.HuY.-h.PengP.WangJ.-m.LiuJ.-y.ChenZ.LiG.ZhengZ.-j.QiuS.-q.LuoJ.YeC.-j.ZhuS.-y.ZhongN.-s.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.3821820201708172010.1056/NEJMoa200203232109013 HanJ.-H.LeeD.ChewC.H.C.KimT.PakJ.J.A multi-virus detectable"/>
  <result pre="immunosensor for the corona virus associated with the Middle East" exact="respiratory" post="syndrome using an array of gold nanoparticle-modified carbon electrodesMicrochimica"/>
  <result pre="for the corona virus associated with the Middle East respiratory" exact="syndrome" post="using an array of gold nanoparticle-modified carbon electrodesMicrochimica Acta186201922430847572"/>
  <result pre="of gold nanoparticle-modified carbon electrodesMicrochimica Acta186201922430847572 LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of" exact="cardiovascular" post="metabolic diseases on COVID-19 in ChinaClin. Res. Cardiol.1095202053153810.1007/s00392-020-01626-932161990 LiH.WangY.M.XuJ.Y.CaoB.[Potential"/>
  <result pre="gold nanoparticle-modified carbon electrodesMicrochimica Acta186201922430847572 LiB.YangJ.ZhaoF.ZhiL.WangX.LiuL.BiZ.ZhaoY.Prevalence and impact of cardiovascular" exact="metabolic diseases" post="on COVID-19 in ChinaClin. Res. Cardiol.1095202053153810.1007/s00392-020-01626-932161990 LiH.WangY.M.XuJ.Y.CaoB.[Potential antiviral therapeutics"/>
  <result pre="implications in cardiovascular, hypertensive and kidney diseasesPharmacol. Res.1252017213828619367 LiY.X.WuW.YangT.ZhouW.FuY.M.FengQ.M.YeJ.M.[Characteristics of" exact="peripheral" post="blood leukocyte differential counts in patients with COVID-19]Zhonghua Nei"/>
  <result pre="MatsuyamaS.KawaseM.NaoN.ShiratoK.UjikeM.KamitaniW.ShimojimaM.FukushiS.The Inhaled Corticosteroid Ciclesonide Blocks Coronavirus RNA Replication by Targeting" exact="Viral" post="NSP15bioRxiv202010.1101/03.11.9870162020 MengL.HuaF.BianZ.Coronavirus disease 2019 (COVID-19): emerging and future challenges"/>
  <result pre="Ciclesonide Blocks Coronavirus RNA Replication by Targeting Viral NSP15bioRxiv202010.1101/03.11.9870162020 MengL.HuaF.BianZ.Coronavirus" exact="disease" post="2019 (COVID-19): emerging and future challenges for dental and"/>
  <result pre="NSP15bioRxiv202010.1101/03.11.9870162020 MengL.HuaF.BianZ.Coronavirus disease 2019 (COVID-19): emerging and future challenges for" exact="dental" post="and oral medicineJ. Dent. Res.202022034520914246 PatelA.JerniganD.B.Initial public health response"/>
  <result pre="and interferon beta against MERS-CoVNat. Commun.11202022231924756 ShiY.TanM.ChenX.LiuY.HuangJ.OuJ.DengX.Immunopathological Characteristics of Coronavirus" exact="Disease" post="2019 Cases in Guangzhou2020medRxivChina10.1101/03.12.200347362020 SinghR.HongS.JangJ.Label-free detection of influenza viruses"/>
  <result pre="sequencing for accurate and comprehensive detection of SARS-CoV-2 and other" exact="respiratory" post="virusesmedRxiv2020200295382003.2004 WHOLaboratory testing for 2019 novel coronavirus (2019-nCoV) in"/>
  <result pre="in suspected human casesWHO/COVID-19/laboratory/2020.42020 WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.YuanM.-L.ZhangY.-L.DaiF.-H.LiuY.WangQ.-M.ZhengJ.-J.XuL.HolmesE.C.ZhangY.-Z.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature579202026526932015508 XiaY.JinR.ZhaoJ.LiW.ShenH.Risk of COVID-19 for cancer patientsLancet"/>
  <result pre="suspected human casesWHO/COVID-19/laboratory/2020.42020 WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.YuanM.-L.ZhangY.-L.DaiF.-H.LiuY.WangQ.-M.ZhengJ.-J.XuL.HolmesE.C.ZhangY.-Z.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature579202026526932015508 XiaY.JinR.ZhaoJ.LiW.ShenH.Risk of COVID-19 for cancer patientsLancet Oncol.2142020e18010.1016/S1470-2045(20)30150-932142622"/>
  <result pre="with human respiratory disease in ChinaNature579202026526932015508 XiaY.JinR.ZhaoJ.LiW.ShenH.Risk of COVID-19 for" exact="cancer" post="patientsLancet Oncol.2142020e18010.1016/S1470-2045(20)30150-932142622 XuB.KraemerM.U.G.OpenC.-D.C.G.Open access epidemiological data from the COVID-19"/>
  <result pre="data from the COVID-19 outbreakLancet Infect. Dis.205202053410.1016/S1473-3099(20)30119-5 XuY.LiuH.HuK.WangM.[Clinical management of" exact="lung cancer" post="patients during the outbreak of 2019 novel coronavirus disease"/>
  <result pre="from the COVID-19 outbreakLancet Infect. Dis.205202053410.1016/S1473-3099(20)30119-5 XuY.LiuH.HuK.WangM.[Clinical management of lung" exact="cancer" post="patients during the outbreak of 2019 novel coronavirus disease"/>
  <result pre="lung cancer patients during the outbreak of 2019 novel coronavirus" exact="disease" post="(COVID-19)]Zhongguo Fei Ai Za Zhi232020 YangL.XuH.Y.WangY.[Diagnostic and therapeutic strategies"/>
  <result pre="(COVID-19)]Zhongguo Fei Ai Za Zhi232020 YangL.XuH.Y.WangY.[Diagnostic and therapeutic strategies of" exact="lung cancer" post="patients during the outbreak of 2019 novel coronavirus disease"/>
  <result pre="Fei Ai Za Zhi232020 YangL.XuH.Y.WangY.[Diagnostic and therapeutic strategies of lung" exact="cancer" post="patients during the outbreak of 2019 novel coronavirus disease"/>
  <result pre="lung cancer patients during the outbreak of 2019 novel coronavirus" exact="disease" post="(COVID-19)]Zhonghua Zhongliu Zazhi422020E006 YangW.DangX.WangQ.XuM.ZhaoQ.ZhouY.ZhaoH.WangL.XuY.WangJ.HanS.WangM.PeiF.WangY.Rapid detection of SARS-CoV-2 using reverse"/>
  <result pre="press ZhangB.ZhouX.ZhuC.FengF.QiuY.FengJ.JiaQ.SongQ.ZhuB.WangJ.Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts" exact="disease" post="severity and outcome for patients with COVID-19medRxiv2020200350482003.2012 ZhangJ.J.DongX.CaoY.Y.YuanY.D.YangY.B.YanY.Q.AkdisC.A.GaoY.D.Clinical Characteristics"/>
  <result pre="suggest multiple outbreak sources of transmissionmedRxiv2020200279532002.2025 ZhaoJ.YangY.HuangH.-P.LiD.GuD.-F.LuX.-F.ZhangZ.LiuL.LiuT.LiuY.-K.HeY.-J.SunB.WeiM.-L.YangG.-Y.WangX.ZhangL.ZhouX.-Y.XingM.-Z.WangP.G.Relationship between the ABO" exact="Blood" post="Group and the COVID-19 SusceptibilitymedRxiv202010.1101/03.11.200310962020 ZhouL.LiuH.G.[Early detection and disease"/>
  <result pre="ABO Blood Group and the COVID-19 SusceptibilitymedRxiv202010.1101/03.11.200310962020 ZhouL.LiuH.G.[Early detection and" exact="disease" post="assessment of patients with novel coronavirus pneumonia]Zhonghua Jiehe He"/>
  <result pre="patients with novel coronavirus pneumonia]Zhonghua Jiehe He Huxi Zazhi43202016717032164079 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.ChenH.-D.ChenJ.LuoY.GuoH.JiangR.-D.LiuM.-Q.ChenY.ShenX.-R.WangX.ZhengX.-S.ZhaoK.ChenQ.-J.DengF.LiuL.-L.YanB.ZhanF.-X.WangY.-Y.XiaoG.-F.ShiZ.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 </snippets>
</snippetsTree>
